Arch Biopartners, Inc. (ARCH.V)
0.86
-0.06
(-6.52%)
CAD |
TSXV |
Sep 18, 16:00
Arch Biopartners Enterprise Value : 61.15M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 61.15M |
| September 17, 2026 | 65.22M |
| September 16, 2026 | 64.54M |
| September 15, 2026 | 63.18M |
| September 14, 2026 | 65.90M |
| September 11, 2026 | 65.22M |
| September 10, 2026 | 64.54M |
| September 09, 2026 | 67.94M |
| September 08, 2026 | 67.94M |
| September 04, 2026 | 72.02M |
| September 03, 2026 | 76.09M |
| September 02, 2026 | 72.70M |
| September 01, 2026 | 71.34M |
| August 31, 2026 | 72.70M |
| August 28, 2026 | 76.77M |
| August 27, 2026 | 67.26M |
| August 26, 2026 | 72.70M |
| August 25, 2026 | 75.41M |
| August 24, 2026 | 81.53M |
| August 21, 2026 | 78.81M |
| August 20, 2026 | 71.34M |
| August 19, 2026 | 77.45M |
| August 18, 2026 | 80.85M |
| August 17, 2026 | 76.77M |
| August 14, 2026 | 78.13M |
| Date | Value |
|---|---|
| August 13, 2026 | 80.85M |
| August 12, 2026 | 77.45M |
| August 11, 2026 | 76.77M |
| August 10, 2026 | 82.21M |
| August 07, 2026 | 74.73M |
| August 06, 2026 | 64.54M |
| August 05, 2026 | 65.90M |
| August 04, 2026 | 59.79M |
| July 31, 2026 | 57.75M |
| July 30, 2026 | 60.47M |
| July 29, 2026 | 61.15M |
| July 28, 2026 | 61.15M |
| July 27, 2026 | 60.47M |
| July 24, 2026 | 61.83M |
| July 23, 2026 | 62.51M |
| July 21, 2026 | 61.15M |
| July 20, 2026 | 60.47M |
| July 17, 2026 | 59.79M |
| July 16, 2026 | 60.47M |
| July 15, 2026 | 60.47M |
| July 14, 2026 | 59.79M |
| July 13, 2026 | 59.11M |
| July 10, 2026 | 61.15M |
| July 09, 2026 | 58.43M |
| July 08, 2026 | 58.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innovotech, Inc. | 4.192M |
| Kane Biotech, Inc. | 7.260M |
| Quest PharmaTech, Inc. | 5.214M |
| BriaCell Therapeutics Corp. | 10.93M |
| Vaxil Bio Ltd. | 0.1137M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.4751M |
| Total Expenses (Quarterly) | 0.4751M |
| EPS Diluted (Quarterly) | -0.007 |
| Earnings Yield | -4.94% |
| Normalized Earnings Yield | -4.930 |